Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers

27 Jan 2022

Abstract excerpt

Immune checkpoint inhibitor therapy has proven efficacy in a subset of colon cancer patients featuring a deficient DNA mismatch repair system or a high microsatellite instability profile. However, there is high demand for more effective biomarkers to expand the colon cancer population responding to ICI therapy. PBK/TOPK, a serine/threonine kinase, plays a role in cell cycle regulation and mitotic progression....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to FOXO transcription factor regulation
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35203508
DOI: 10.3390/biomedicines10020299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon CancersPMID 35203508Read ↗

PRKCB is a novel and potential biomarker in colon cancer and shapes an inflamed tumor immune microenvironmentSemantic proximity Read ↗

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.Semantic proximity Read ↗

Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon CancerSemantic proximity Read ↗

Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironmentSemantic proximity Read ↗

Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.Semantic proximity Read ↗

Integrated multi-omics unveils novel immune signature for predicting prognosis in colon cancer patientsSemantic proximity Read ↗

Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.Semantic proximity Read ↗

Multi-OMICs data analysis identifies molecular features correlating with tumor immunity in colon cancer.Semantic proximity Read ↗

Immune ULBP1 is Elevated in Colon Adenocarcinoma and Predicts PrognosisSemantic proximity Read ↗

Exploration of the role of tumor mutation burden in clinical significance, immunotherapy response predictor and immune cell infiltration in colon cancerSemantic proximity Read ↗

Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.Semantic proximity Read ↗

Two immune-enhanced molecular subtypes differ in inflammation, immune checkpoints, mutations, and prognostic outcome in stage I-II colonic carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.